bupropion hydrochloride - Profile

What are the generic sources for bupropion hydrochloride and what is the scope of freedom to operate?

Bupropion hydrochloride is the generic ingredient in eight branded drugs marketed by Accord Hlthcare, Actavis Labs Fl Inc, Anbison Lab, Annora Pharma, Aurobindo Pharma Usa, Chartwell Rx, Epic Pharma Llc, Granules, Graviti Pharms, Impax Labs, Invagen Pharms, Ipca Labs Ltd, Jubilant Generics, Lupin, Ph Health, Prinston Inc, Rising, Sandoz, Sciegen Pharms, Sinotherapeutics Inc, Sun Pharm, Torrent, Twi Pharms, Watson Labs Inc, Wockhardt Ltd, Yichang Humanwell, Zhejiang Jutai Pharm, Zydus Pharms, Glaxosmithkline, Bausch, Alembic, Apotex, Cadila Pharms Ltd, Heritage Pharma, Invatech, Micro Labs, Senores Pharms, Axsome, and Nalpropion, and is included in sixty-nine NDAs. There are one hundred and forty-nine patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Bupropion hydrochloride has one patent family member in one country.

Summary for bupropion hydrochloride

International Patents:	1
US Patents:	149
Tradenames:	8
Applicants:	39
NDAs:	69
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for bupropion hydrochloride

Paragraph IV (Patent) Challenges for BUPROPION HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FORFIVO XL	Extended-release Tablets	bupropion hydrochloride	450 mg	022497	1	2013-02-28
WELLBUTRIN XL	Extended-release Tablets	bupropion hydrochloride	150 mg and 300 mg	021515	1	2004-09-21

US Patents and Regulatory Information for bupropion hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Accord Hlthcare	BUPROPION HYDROCHLORIDE	bupropion hydrochloride	TABLET, EXTENDED RELEASE;ORAL	210497-001	Oct 31, 2018	AB3	RX	No	No
Accord Hlthcare	BUPROPION HYDROCHLORIDE	bupropion hydrochloride	TABLET, EXTENDED RELEASE;ORAL	210497-002	Oct 31, 2018	AB3	RX	No	No
Actavis Labs Fl Inc	BUPROPION HYDROCHLORIDE	bupropion hydrochloride	TABLET, EXTENDED RELEASE;ORAL	079095-001	Mar 24, 2009	AB1	RX	No	No
Actavis Labs Fl Inc	BUPROPION HYDROCHLORIDE	bupropion hydrochloride	TABLET, EXTENDED RELEASE;ORAL	077715-001	Nov 26, 2008	AB3	RX	No	No
Actavis Labs Fl Inc	BUPROPION HYDROCHLORIDE	bupropion hydrochloride	TABLET, EXTENDED RELEASE;ORAL	079094-001	Mar 24, 2009	AB2	RX	No	Yes
Actavis Labs Fl Inc	BUPROPION HYDROCHLORIDE	bupropion hydrochloride	TABLET, EXTENDED RELEASE;ORAL	079095-002	Mar 24, 2009	AB1	RX	No	No
Actavis Labs Fl Inc	BUPROPION HYDROCHLORIDE	bupropion hydrochloride	TABLET, EXTENDED RELEASE;ORAL	079095-003	Mar 24, 2009	AB1	RX	No	No

Expired US Patents for bupropion hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline	WELLBUTRIN SR	bupropion hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020358-001	Oct 4, 1996	5,763,493
Glaxosmithkline	WELLBUTRIN	bupropion hydrochloride	TABLET;ORAL	018644-002	Dec 30, 1985	4,393,078
Glaxosmithkline	WELLBUTRIN	bupropion hydrochloride	TABLET;ORAL	018644-003	Dec 30, 1985	4,347,257
Glaxosmithkline	WELLBUTRIN	bupropion hydrochloride	TABLET;ORAL	018644-003	Dec 30, 1985	4,425,363
Bausch	WELLBUTRIN XL	bupropion hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021515-001	Aug 28, 2003	6,143,327
Bausch	WELLBUTRIN XL	bupropion hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021515-001	Aug 28, 2003	6,096,341
Bausch	WELLBUTRIN XL	bupropion hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021515-002	Aug 28, 2003	6,096,341

International Patents for bupropion hydrochloride

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2008038155

Supplementary Protection Certificates for bupropion hydrochloride

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2316456	122017000109	Germany		PRODUCT NAME: NALTREXON ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE NALTREXONHYDROCHLORID, UND BUPROPION ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE BUPROPIONHYDROCHLORID; REGISTRATION NO/DATE: EU/1/14/988 20150326
2316456	300918	Netherlands		PRODUCT NAME: NALTREXON OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER NALTREXONHYDROCHLORIDE, EN BUPROPION OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER BUPROPIONHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/14/988 20150330
2316456	SPC/GB17/078	United Kingdom		PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE.; REGISTERED: UK EU/1/14/988 20150330; UK PLGB 50742/0001 20150330
2316456	C 2017 047	Romania		PRODUCT NAME: COMBINATIE DE NALTREXONA SAU O SARE ACCEPTABILA FARMACEUTIC A ACESTEIA, IN PARTICULAR CLORHIDRAT DE NALTREXONA SI BUPROPION SAU O SARE ACCEPTABILA FARMACEUTIC A ACESTUIA, IN PARTICULAR CLORHIDRAT DE BUPROPION; NATIONAL AUTHORISATION NUMBER: EU/1/14/988; DATE OF NATIONAL AUTHORISATION: 20150326; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/988; DATE OF FIRST AUTHORISATION IN EEA: 20150326
2316456	132017000142109	Italy		PRODUCT NAME: NALTREXONE/BUPROPIONE(MYSIMBA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/988, 20150330
2316456	2017/059	Ireland		PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/14/988 20150326
2316456	1790064-8	Sweden		PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE; REG. NO/DATE: EU/1/14/988 20150330

Bupropion Hydrochloride: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Summary

Bupropion hydrochloride is a well-established antidepressant and smoking cessation aid marketed globally. Its market presence is sustained through diverse therapeutic indications, a broad demographic reach, and ongoing pipeline developments. This analysis examines its current investment landscape, market dynamics, competitive positioning, regulatory environment, and financial outlook. Strategic insights are provided to inform decision-making for stakeholders considering investments or licensing opportunities.

---

What Is the Current Investment Landscape for Bupropion Hydrochloride?

Market Overview

Parameter	Data	Source/Period
Global Market Size (2022)	~$480 million	[1]
CAGR (2023-2028)	3.1%	[1]
Major Brands	Wellbutrin (GlaxoSmithKline), Forfivo (Indivior)	N/A

Revenue Breakdown by Region (2022)

Region	Revenue (USD millions)	Market Share	Key Drivers
North America	60%	~$288	Established prescription base, high awareness of smoking cessation programs
Europe	20%	~$96	Increasing mental health awareness, regulatory approvals
Asia-Pacific	15%	~$72	Growing mental health treatment, emerging generics
Rest of the World	5%	~$24	Limited access, emerging markets

Major Market Players

Company	Market Share	Key Products	Strategic Moves
GlaxoSmithKline	~40%	Wellbutrin, Aplenzin	Patent expiries, generic entry
Indivior	~20%	Forfivo, VRAYLAR	Focus on niche formulations
Teva	~15%	Generic bupropion	Expanding generic portfolio
Others (Mylan, Apotex, etc.)	~25%	Generics	Price competition, margin pressures

Investment Trends

• Patent Expirations: The primary patents expired in 2017-2018, leading to generic proliferation and revenue decline for branded formulations.
• Generic Market Entry: Driven by patent cliff, with multiple players offering bioequivalent products.
• Pipeline and Line Extensions: Companies investing in extended-release formulations, combination therapies, and digital health adjuncts to sustain revenue.

---

What Are the Market Dynamics Influencing Bupropion Hydrochloride?

Therapeutic Indications and Market Drivers

Indication	Market Size (2022)	Growth Drivers	Challenges
Major Depressive Disorder (MDD)	~$6 billion	Rising mental health awareness, stigma reduction	Competition from SSRIs, SNRIs
Smoking Cessation	~$150 million	Effective efficacy, Fewer side effects	Availability of alternatives (varenicline), consumer preference shifts
ADHD, Neuropathic pain (off-label)	Growing	Ongoing research	Limited formal approval

Regulatory Environment

• FDA Approvals: Bupropion is FDA-approved for MDD, SAD, smoking cessation, and off-label uses.
• Patent and Exclusivity Status: Multiple patents expired, leading to a generic-dominated market.
• Regulatory Challenges: Ongoing monitoring of safety signals such as risk of seizures at high doses.

Competitive Landscape

• Generic Entrants: Significant, reducing profit margins for branded drugs.
• Innovative Alternatives: Newer antidepressants (e.g., vortioxetine) and smoking cessation aids (e.g., varenиклин) impacting market share.
• Digital health integration: Telemedicine and adherence apps are influencing prescription and compliance patterns.

---

What Is the Projected Financial Trajectory?

Revenue Projections (2023-2028)

Year	Projected Revenue (USD millions)	Assumptions	Notes
2023	~$430	Post-patent loss adjustments	Increased generic competition
2024	~$410	Market saturation	Entry of biosimilars impacts sales
2025	~$390	Growing awareness, new formulations	Potential line extensions
2026	~$370	Price erosion	Competitive pricing persists
2027	~$350	Market stabilization	Focus on niche markets
2028	~$340	Mature phase	Slight decline anticipated

Profitability and Margins

Metric	2022	2026	2028
Gross Margin (%)	60%	55%	50%
Operating Margin (%)	20%	15%	10%
Net Margin (%)	15%	10%	8%

Investment Outlook

• The decline in revenues indicates a mature product; upside potential depends on line extensions or pipeline successes.
• Mergers and acquisitions of generics players can impact market share dynamics.
• Potential for biosimilar or reformulation-driven growth exists but requires significant R&D investments.

---

How Do Comparative Drugs and Market Trends Impact Investment?

Key Comparators

Drug	Indication	Market Size	Patent Expiry	Positioning
Vortioxetine (Trintellix)	MDD	~$1.2 billion	2019	Niche, branded
Varenicline (Chantix)	Smoking cessation	~$900 million	2017	Competition
Bupropion (generic)	MDD, smoking cessation	<$400 million	–	Market share declining

Market Evolution Factors

• Shift Toward Personalized Medicine: Favoring targeted therapies, reducing reliance on broad-spectrum antidepressants.
• Regulatory and Reimbursement Policies: Healthcare reforms may pressure prices further.
• Digital and Behavioral Health: Integration could revive older drugs with adjunctive support.

---

Deep-Dive Comparison: Investment Considerations vs. Alternatives

Aspect	Bupropion Hydrochloride	Alternatives (SSRIs, Varenicline)	Impact on Investment
Patent Status	Expired	Patent-protected	Increased generics, lower revenue
Revenue Stability	Declining	Variable	Need for diversification
Market Penetration	Mature	Growing niches	Growth potential in specific indications
Innovation Pipeline	Moderate	Active	Opportunities for line extensions

Key Investment Risks and Opportunities

Risks	Opportunities
Patent expiration leading to revenue loss	Development of new formulations, combination drugs
Increased generic competition	Targeting niche markets such as therapy-resistant depression
Regulatory changes affecting labeling/safety	Expanding indications via approved clinical trials
Market saturation	Digital health integration to improve adherence

---

Conclusion

Bupropion hydrochloride presents a mature, low-growth investment profile shaped by patent expiries and intense generic competition. While revenue declines are expected, opportunities exist in niche markets, extended-release formulations, and digital health integration. Investors should monitor pipeline developments and regulatory trends, considering diversification strategies to mitigate declining margins.

---

Key Takeaways

• Market size is approximately USD 480 million globally, with a modest CAGR driven by generic competition.
• Revenue decline is projected over the next five years, emphasizing the importance of innovation.
• Patent expiries in 2017-2018 catalyzed generics, eroding profit margins.
• Pipeline efforts focusing on extended-release formulations or combination therapies may offset revenue declines.
• Market dynamics favor niche and personalized medicine approaches, signaling cautious investment in mature formulations.

---

FAQs

1. What are the main drivers of revenue decline for bupropion hydrochloride?
   Patent expirations and the proliferation of cheaper generic alternatives contribute to revenue erosion, compounded by market saturation and competition from newer therapeutics.

2. Are there opportunities to extend the commercial life of bupropion hydrochloride?
   Yes. Line extensions, such as extended-release formulations, combination therapies, or new indications through clinical trials, offer potential avenues.

3. How does regulatory risk affect future investment?
   Regulatory agencies continuously monitor safety signals, and label changes can impact sales. However, approved off-label uses, if supported by clinical data, may sustain demand.

4. What role do digital health tools play in the current market trajectory?
   Digital tools can improve adherence and monitoring, potentially increasing the drug’s efficacy profile and opening new market segments.

5. Should investors diversify into related therapeutic areas?
   Diversification into newer antidepressant classes or smoking cessation agents with patent protections can mitigate risks associated with declining bupropion revenues.

---

References

[1] MarketsandMarkets, "Psychiatric Drugs Market by Type," 2022 Report.